Study S001676

Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity for Metformin Non-responders: a Single-blind Randomized Control Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05333003
Acronym: Sema
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: SINGLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 92
Start: 2022-05-25
Primary completion: 2026-08
Lead sponsor: Centre for Addiction and Mental Health
Conditions: Schizophrenia Spectrum Disorders
Interventions: DRUG:Semaglutide; OTHER:Placebo
Results posted: FALSE

Registered primary outcomes

Weight change [32 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.